Publications by authors named "Christianne Pang"
Type 2 diabetes is a chronic, progressive disease, and its management results in a high emotional burden on patients. Eventually many patients require and can benefit from the use of insulin. This article reports results of a survey of patients and health care providers regarding their experiences of and challenges with the use of basal insulin.
View Article and Find Full Text PDFBackground: We aimed to evaluate patient preferences towards three oral antihyperglycaemic therapies using conjoint analysis to determine which attributes may influence use.
Methods: We used an online survey, completed by 553 US respondents with type 2 diabetes mellitus (T2DM; mean age 64 ± 9 years; 55% had cardiovascular [CV] risk; 27% had CV disease), to present hypothetical, blinded, pairwise, drug profile comparison choices, between different benefit/risk attributes and effect ranges. Attributes were derived from phase 3 trials for empagliflozin 25 mg (SGLT2 inhibitor), oral semaglutide 14 mg (GLP-1 receptor agonist) and sitagliptin 100 mg (DPP-4 inhibitor).
Article Synopsis
- * Methods: An online survey with 701 T1D patients from the U.S., Canada, and Germany utilized conjoint analysis to evaluate preferences among different drug profiles based on various benefit-risk factors derived from phase 3 trial data.
- * Results: The findings showed that patients prioritized the risk of diabetic ketoacidosis, with a low-dose SGLTi being the most preferred option, chosen by 83% of respondents, compared to other therapies.
Adjunct therapy can help patients with type 1 diabetes achieve glycemic goals while potentially mitigating some of the side effects of insulin. In this study, we used a patient survey to identify the unmet needs in type 1 diabetes therapy, patient views of treatment benefit-risk trade-offs, and patient preferences for the use of an adjunct therapy. A quantitative survey was sent to 2084 adults with type 1 diabetes in November 2017.
View Article and Find Full Text PDF